Cipher Pharmaceuticals Inc. Annual and Special Meeting of Shareholders



    Toronto Stock Exchange Symbol: DND

    MISSISSAUGA, ON, April 12 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND)
today announced it will hold its Annual and Special Meeting of Shareholders on
Tuesday, April 17, 2007 at 4:30 p.m. ET.

    
    WHAT:     CIPHER PHARMACEUTICALS INC. ANNUAL AND SPECIAL MEETING OF
              SHAREHOLDERS

    WHERE:    TORONTO BOARD OF TRADE
              1 FIRST CANADIAN PLACE
              TORONTO, ONTARIO

    WHEN:     TUESDAY, APRIL 17 AT 4:30 P.M. ET
    

    A live audio webcast of the meeting will be available at www.newswire.ca
and www.cipherpharma.com. Please connect at least 15 minutes prior to the
start of the meeting to ensure adequate time for any software download that
may be required to join the webcast.

    About Cipher Pharmaceuticals Inc.

    Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher's strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher's
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. Cipher
currently has three late-stage drugs in its pipeline. The Company's lead
compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug
Administration and Health Canada in the first quarter of 2006. In addition,
Cipher is developing formulations of the pain reliever tramadol (currently
under regulatory review by the FDA) and the acne treatment isotretinoin
(currently under regulatory review by the FDA).
    Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and
has approximately 24 million shares outstanding. For more information, please
visit www.cipherpharma.com.





For further information:

For further information: Craig Armitage, Investor Relations, The Equicom
Group, (416) 815-0700 ext 278, (416) 815-0080 fax, carmitage@equicomgroup.com;
Larry Andrews, President & Chief Executive Officer, Cipher Pharmaceuticals,
(905) 602-5840 ext 24, (905) 602-0628 fax, landrews@cipherpharma.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890